MedTrace Logo

Dynamic Whole Body PET/ MRI

NCT04495959 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-01-08

No results posted yet for this study

Summary

Prostate cancer is the third most common cause of cancer death in men. Most patients with localized prostate cancer will be cured with surgery or radiation therapy, but up to 35% of patients will have their prostate cancer return.Current conventional imaging modalities have limitations particularly at low prostate specific antigen levels. This study proposes to use 68Ga-HTK03149 Dynamic Whole Body (DWB) Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) scans which targets prostate-specific membrane antigens (PSMA) to detect where in the body the prostate cancer has recurred.

Conditions

  • Prostatic Cancer

Interventions

DRUG

68Ga-HTK03149

PET/MRI scan with radiotracer 68Ga-HTK03149

Sponsors & Collaborators

  • British Columbia Cancer Agency

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-09-30
Completion
2028-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04495959 on ClinicalTrials.gov